97 related articles for article (PubMed ID: 29767447)
1. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients.
Bram Ednersson S; Stenson M; Stern M; Enblad G; Fagman H; Nilsson-Ehle H; Hasselblom S; Andersson PO
Br J Haematol; 2018 Jun; 181(6):770-781. PubMed ID: 29767447
[TBL] [Abstract][Full Text] [Related]
2. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
3. c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Filipovic B; Radovanović S; Zdravković M; Stanisavljevic D; Mihaljevic B
Biomed Pharmacother; 2013 Jun; 67(5):445-9. PubMed ID: 23582793
[TBL] [Abstract][Full Text] [Related]
4. Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.
Stenson M; Pedersen A; Hasselblom S; Nilsson-Ehle H; Karlsson BG; Pinto R; Andersson PO
Leuk Lymphoma; 2016 Aug; 57(8):1814-22. PubMed ID: 26887805
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
[TBL] [Abstract][Full Text] [Related]
6. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
7. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.
Rüetschi U; Stenson M; Hasselblom S; Nilsson-Ehle H; Hansson U; Fagman H; Andersson PO
Int J Proteomics; 2015; 2015():841769. PubMed ID: 26060582
[TBL] [Abstract][Full Text] [Related]
8. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
Rodig SJ; Savage KJ; LaCasce AS; Weng AP; Harris NL; Shipp MA; Hsi ED; Gascoyne RD; Kutok JL
Am J Surg Pathol; 2007 Jan; 31(1):106-12. PubMed ID: 17197926
[TBL] [Abstract][Full Text] [Related]
9. Possible Role of GADD45γ Methylation in Diffuse Large B-Cell Lymphoma: Does It Affect the Progression and Tissue Involvement?
Barış İC; Caner V; Şen Türk N; Sarı İ; Hacıoğlu S; Doğu MH; Çetin O; Tepeli E; Can Ö; Bağcı G; Keskin A
Turk J Haematol; 2015 Dec; 32(4):295-303. PubMed ID: 25912017
[TBL] [Abstract][Full Text] [Related]
10. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
11. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
Linderoth J; Edén P; Ehinger M; Valcich J; Jerkeman M; Bendahl PO; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
Br J Haematol; 2008 May; 141(4):423-32. PubMed ID: 18419622
[TBL] [Abstract][Full Text] [Related]
12. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
13. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
14. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma].
Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497
[TBL] [Abstract][Full Text] [Related]
18. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay.
Kim SJ; Sohn I; Do IG; Jung SH; Ko YH; Yoo HY; Paik S; Kim WS
Ann Hematol; 2014 Mar; 93(3):437-47. PubMed ID: 23975159
[TBL] [Abstract][Full Text] [Related]
20. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
